Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era

被引:69
作者
Armand, Philippe [1 ]
Welch, Sarah [2 ]
Kim, Haesook T. [3 ]
LaCasce, Ann S. [1 ]
Jacobsen, Eric D. [1 ]
Davids, Matthew S. [1 ]
Jacobson, Caron [1 ]
Fisher, David C. [1 ]
Brown, Jennifer R. [1 ]
Coughlin, Erin [4 ]
Freedman, Arnold S. [1 ]
Chen, Yi-Bin [4 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[2] Boston Univ, Sch Med, Div Grad Med Sci, Boston, MA 02118 USA
[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA
[4] Massachusetts Gen Hosp, Div Hematol Oncol, Bone Marrow Transplant Unit, Boston, MA 02114 USA
关键词
prognostic factors; autologous stem cell transplant; diffuse large B-cell lymphoma; transformed indolent lymphoma; PET; HIGH-DOSE THERAPY; BONE-MARROW-TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; FOLLICULAR LYMPHOMA; CHEMOTHERAPY; RITUXIMAB; SURVIVAL; SUPPORT; SCAN; CHOP;
D O I
10.1111/bjh.12176
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the positron emission tomography (PET) era, traditional prognostic factors may not apply for patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) undergoing autologous stem cell transplantation (ASCT). Moreover, little is known about prognostic factors in patients transplanted for transformed indolent lymphoma (TIL). We conducted a retrospective study of 143 patients with R/R DLBCL and TIL who were transplanted in the last decade and had a post-salvage PET scan. We examined prognostic factors in both groups, and constructed a prognostic score for DLBCL patients. For patients with DLBCL, post-salvage PET response was an important prognostic factor. Advanced age and symptomatic relapse were also significantly associated with outcome. A simple score could stratify patients into three risk groups with 4-year post-ASCT overall survival of 84%, 59%, and 10%, and 4-year progression-free survival of 67%, 41% and 0% (P<0 center dot 0001 for both). However, none of those factors (including PET response to salvage) appeared relevant for patients with TIL, despite their comparable overall outcome. Our prognostic score for DLBCL patients undergoing ASCT may be useful for prognostication, for stratification in clinical trials, and to motivate the design of new strategies for patients in the high-risk group, who may not derive benefit from standard ASCT.
引用
收藏
页码:608 / 617
页数:10
相关论文
共 30 条
[21]   Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant [J].
Lane, Andrew A. ;
Armand, Philippe ;
Feng, Yang ;
Neuberg, Donna S. ;
Abramson, Jeremy S. ;
Brown, Jennifer R. ;
Fisher, David C. ;
LaCasce, Ann S. ;
Jacobsen, Eric D. ;
McAfee, Steven L. ;
Spitzer, Thomas R. ;
Freedman, Arnold S. ;
Chen, Yi-Bin .
LEUKEMIA & LYMPHOMA, 2012, 53 (06) :1130-1136
[22]   CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group [J].
Pfreundschuh, Michael ;
Kuhnt, Evelyn ;
Truemper, Lorenz ;
Osterborg, Anders ;
Trneny, Marek ;
Shepherd, Lois ;
Gill, Devinder S. ;
Walewski, Jan ;
Pettengell, Ruth ;
Jaeger, Ulrich ;
Zinzani, Pier-Luigi ;
Shpilberg, Ofer ;
Kvaloy, Stein ;
Brown, Peter de Nully ;
Stahel, Rolf ;
Milpied, Noel ;
Lopez-Guillermo, Armando ;
Poeschel, Viola ;
Grass, Sandra ;
Loeffler, Markus ;
Murawski, Niels .
LANCET ONCOLOGY, 2011, 12 (11) :1013-1022
[23]   AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA [J].
PHILIP, T ;
GUGLIELMI, C ;
HAGENBEEK, A ;
SOMERS, R ;
VANDERLELIE, H ;
BRON, D ;
SONNEVELD, P ;
GISSELBRECHT, C ;
CAHN, JY ;
HAROUSSEAU, JL ;
COIFFIER, B ;
BIRON, P ;
MANDELLI, F ;
CHAUVIN, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) :1540-1545
[24]   Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients [J].
Roland, V. ;
Bodet-Milin, C. ;
Moreau, A. ;
Gastinne, T. ;
Mahe, B. ;
Dubruille, V. ;
Maisonneuve, H. ;
Juge-Morineau, N. ;
Moreau, P. ;
Jardel, H. ;
Planche, L. ;
Mohty, M. ;
Moreau, P. ;
Harousseau, J-L ;
Kraeber-Bodere, F. ;
Le Gouill, S. .
BONE MARROW TRANSPLANTATION, 2011, 46 (03) :393-399
[25]   Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma [J].
Schot, Bart W. ;
Zijlstra, Josee M. ;
Sluiter, Wilm J. ;
van Imhoff, Gustaaf W. ;
Pruim, Jan ;
Vaalburg, Willem ;
Vellenga, Edo .
BLOOD, 2007, 109 (02) :486-491
[26]   A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].
SHIPP, MA ;
HARRINGTON, DP ;
ANDERSON, JR ;
ARMITAGE, JO ;
BONADONNA, G ;
BRITTINGER, G ;
CABANILLAS, F ;
CANELLOS, GP ;
COIFFIER, B ;
CONNORS, JM ;
COWAN, RA ;
CROWTHER, D ;
DAHLBERG, S ;
ENGELHARD, M ;
FISHER, RI ;
GISSELBRECHT, C ;
HORNING, SJ ;
LEPAGE, E ;
LISTER, TA ;
MEERWALDT, JH ;
MONTSERRAT, E ;
NISSEN, NI ;
OKEN, MM ;
PETERSON, BA ;
TONDINI, C ;
VELASQUEZ, WA ;
YEAP, BY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994
[27]   High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma [J].
Smith, Stephen D. ;
Bolwell, Brian J. ;
Advani, Anjali S. ;
Andresen, Steven W. ;
Chan, Josephine L. ;
Dean, Robert M. ;
Hsi, Eric D. ;
Kalaycio, Matt E. ;
Pohlman, Brad L. ;
Rybicki, Lisa A. ;
Sweetenham, John W. .
LEUKEMIA & LYMPHOMA, 2009, 50 (10) :1625-1631
[28]   Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study [J].
Trneny, Marek ;
Bosly, Andre ;
Bouabdallah, Krimo ;
Ma, David ;
Shpilberg, Ofer ;
Montoto, Silvia ;
Sebban, Catherine ;
Hagberg, Hans ;
Moskowitz, Craig H. ;
Schmitz, Norbert ;
Gisselbrecht, Christian .
BLOOD, 2009, 114 (22) :363-363
[29]   Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience [J].
Ulrickson, Matthew ;
Aldridge, Julie ;
Kim, Haesook T. ;
Hochberg, Ephraim P. ;
Hammerman, Peter ;
Dube, Christine ;
Attar, Eyal ;
Ballen, Karen K. ;
Dey, Bimalangshu R. ;
McAfee, Steven L. ;
Spitzer, Thomas R. ;
Chen, Yi-Bin .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (11) :1447-1454
[30]   High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: A case-matched study from the European bone marrow transplant registry [J].
Williams, CD ;
Harrison, CN ;
Lister, TA ;
Norton, AJ ;
Blystad, AK ;
Coiffier, B ;
Taghipour, G ;
Schmitz, N ;
Goldstone, AH .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :727-735